Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effectiveness Of Priority Review Voucher, Orphan Status Part Of Tropical Disease Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

September public hearing will continue FDA's look into rare and neglected disease drug development.

You may also be interested in...



FDA To Offer Reviewers Rare Disease Training; Patient Groups Want Separate ODE

FDA will offer training next year for reviewers to better understand rare diseases and their associated product applications that could help speed the approval process, although it appears to be optional.

FDA To Offer Reviewers Rare Disease Training; Patient Groups Want Separate ODE

FDA will offer training next year for reviewers to better understand rare diseases and their associated product applications that could help speed the approval process, although it appears to be optional.

Priority Review Voucher's Uncertain Value May Hinder Development

FDA’s innovative priority review voucher, intended to incentivize the development of new drugs for neglected diseases, may actually have created a hurdle in some cases.

Related Content

Topics

UsernamePublicRestriction

Register

PS070929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel